Alzheimer's disease drug diranersen demonstrates clinical benefit
At the Clinical Trials on Alzheimer's Disease conference, the CELIA trial results announced that diranersen demonstrates increasing clinical benefit in early Alzheimer's disease.
Dr Richard Oakley, Associate Director for Research and Innovation at Alzheimer’s Society, said:
'Alzheimer’s disease is complex, but we know that the build-up of two proteins in the brain, amyloid and tau, play an important role in its development.
'While many recent scientific advances have focused on amyloid, we urgently need treatments that tackle Alzheimer’s disease in different ways.
About diranersen, a potential new treatment
'Diranersen is a particularly interesting therapy because it targets tau at its source. It works a bit like a gene "off-switch", reducing the amount of tau the brain produces rather than trying to clear it once it has already built up.
'The treatment is given via lumbar puncture into the fluid around the spinal cord.
'The latest clinical trial results for this drug are very encouraging. They suggest that diranersen effectively reduces the build up of tau in the brain, and the treatment’s ability to slow worsening of memory and thinking problems increases over two years.
A new treatment for Alzheimer's disease could be on the horizon
If these promising findings are confirmed in the upcoming phase three trial, a significant new treatment option for early Alzheimer’s disease could be within touching distance.
'Research is making huge progress and will beat dementia – and as more potential treatments emerge, it’s more important than ever that people get an early and accurate dementia diagnosis so they can benefit from them.
'We look forward to seeing the full results from this trial and how this drug progresses.'
Take part in dementia research
Research is only possible thanks to the people who participate. If you would like to get involved in dementia research, we can support you.